14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $31.23 $31.23 Wednesday, 1st May 2024 IMGN stock ended at $31.23. During the day the stock fluctuated 0% from a day low at $31.23 to a day high of $31.23.
90 days $29.21 $31.25
52 weeks $10.31 $31.25

Historical ImmunoGen prices

Date Open High Low Close Volume
Aug 21, 2023 $15.65 $16.27 $15.53 $16.11 1 987 903
Aug 18, 2023 $15.58 $16.03 $15.58 $15.64 2 855 937
Aug 17, 2023 $16.06 $16.07 $15.67 $15.70 2 780 112
Aug 16, 2023 $15.47 $16.19 $15.45 $16.09 4 371 925
Aug 15, 2023 $15.12 $15.82 $15.04 $15.56 4 149 364
Aug 14, 2023 $14.22 $15.24 $14.19 $15.12 5 027 479
Aug 11, 2023 $14.06 $14.65 $13.97 $14.37 3 492 650
Aug 10, 2023 $14.25 $14.51 $13.83 $14.09 5 427 602
Aug 09, 2023 $14.11 $14.47 $13.96 $14.38 4 505 795
Aug 08, 2023 $14.48 $14.71 $14.07 $14.14 7 333 523
Aug 07, 2023 $16.80 $16.80 $14.21 $14.33 16 761 008
Aug 04, 2023 $16.65 $17.21 $16.65 $17.06 6 014 360
Aug 03, 2023 $17.00 $17.02 $16.49 $16.58 7 582 371
Aug 02, 2023 $18.15 $18.15 $17.14 $17.17 5 319 396
Aug 01, 2023 $17.82 $18.41 $17.46 $18.25 5 554 189
Jul 31, 2023 $19.19 $19.17 $16.78 $17.82 13 741 422
Jul 28, 2023 $18.49 $19.78 $18.41 $19.52 5 626 542
Jul 27, 2023 $18.37 $18.49 $17.90 $18.46 5 885 738
Jul 26, 2023 $17.89 $18.04 $17.63 $17.94 2 708 721
Jul 25, 2023 $18.18 $18.48 $18.03 $18.08 2 613 706
Jul 24, 2023 $19.01 $19.01 $16.94 $18.20 4 932 240
Jul 21, 2023 $19.17 $19.51 $18.97 $18.99 2 315 757
Jul 20, 2023 $19.66 $19.73 $18.95 $19.09 2 819 649
Jul 19, 2023 $19.55 $20.69 $19.59 $19.87 6 610 392
Jul 18, 2023 $19.49 $19.68 $19.14 $19.44 2 275 312
Click to get the best stock tips daily for free!

About ImmunoGen

ImmunoGen ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and... IMGN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT